Ca2+/calmodulin-dependent Protein Kinase II Alpha is Required for the Initiation and Maintenance of Opioid-induced Hyperalgesia

Overview

Journal J Neurosci

Specialty Neurology

Date 2010 Jan 8

PMID 20053885

Citations 42

Authors

Yan Chen

Cheng Yang

Zaijie Jim Wang

Affiliations

Soon will be listed here.

Abstract

Repeated administration of opioids not only leads to tolerance and dependence, but also results in nociceptive enhancement called opioid-induced hyperalgesia (OIH). Nociceptive mediators involved in OIH generation remain poorly understood. In the present study, we tested the hypothesis that Ca(2+)/calmodulin-depent protein kinase II (CaMKIIalpha) is critical for OIH. Opioid-induced hyperalgesia was produced by repeated morphine administration or pellet implantation in mice. Correlating with the development of tactile allodynia and thermal hyperalgesia, spinal CaMKIIalpha activity was significantly increased in OIH. KN93, a CaMKII inhibitor, dose- and time-dependently reversed OIH and CaMKII activation without impairing locomotor coordination. To elucidate the specific CaMKII isoform involved, we targeted CaMKIIalpha by using small interfering RNA and demonstrated that knockdown of spinal CaMKIIalpha attenuated OIH. Furthermore, morphine failed to induce OIH in CaMKIIalpha(T286A) point mutant mice, although wild-type littermate mice developed robust OIH after repeated treatments with morphine. These data implicate, for the first time, an essential role of CaMKIIalpha as a cellular mechanism leading to and maintaining opioid-induced hyperalgesia.

Citing Articles

Morphine-induced hyperalgesia impacts small extracellular vesicle miRNA composition and function.

Reddy D, Lin Z, Ramanathan S, Luo X, Pande R, Tian Y bioRxiv. 2024; .

PMID: 39484599 PMC: 11526852. DOI: 10.1101/2024.10.17.617815.

BDNF/TrkB Signaling Inhibition Suppresses Astrogliosis and Alleviates Mechanical Allodynia in a Partial Crush Injury Model.

Phan T, Jayathilake N, Lee K, Park J Exp Neurobiol. 2023; 32(5):343-353.

PMID: 37927132 PMC: 10628862. DOI: 10.5607/en23031.

Gut microbiota dysbiosis alters chronic pain behaviors in a humanized transgenic mouse model of sickle cell disease.

Kashyap Y, Wang Z Pain. 2023; 165(2):423-439.

PMID: 37733476 PMC: 10843763. DOI: 10.1097/j.pain.0000000000003034.

The role of the gut microbiome and microbial metabolism in mediating opioid-induced changes in the epigenome.

Kolli U, Roy S Front Microbiol. 2023; 14:1233194.

PMID: 37670983 PMC: 10475585. DOI: 10.3389/fmicb.2023.1233194.

PACAP-PAC1 receptor inhibition is effective in opioid induced hyperalgesia and medication overuse headache models.

Bertels Z, Mangutov E, Siegersma K, Cropper H, Tipton A, Pradhan A iScience. 2023; 26(2):105950.

PMID: 36756376 PMC: 9900514. DOI: 10.1016/j.isci.2023.105950.

References

Fukunaga K, Soderling T, Miyamoto E . Activation of Ca2+/calmodulin-dependent protein kinase II and protein kinase C by glutamate in cultured rat hippocampal neurons. J Biol Chem. 1992; 267(31):22527-33. View

Angst M, Clark J . Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006; 104(3):570-87. DOI: 10.1097/00000542-200603000-00025. View

Fang L, Wu J, Lin Q, Willis W . Calcium-calmodulin-dependent protein kinase II contributes to spinal cord central sensitization. J Neurosci. 2002; 22(10):4196-204. PMC: 6757653. DOI: 20026343. View

Gao L, Blair L, Marshall J . CaMKII-independent effects of KN93 and its inactive analog KN92: reversible inhibition of L-type calcium channels. Biochem Biophys Res Commun. 2006; 345(4):1606-10. DOI: 10.1016/j.bbrc.2006.05.066. View

Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S . Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med. 2005; 11(3):263-70. DOI: 10.1038/nm1191. View

Baraldi P, Nunez M, Morelli A, Falzoni S, Di Virgilio F, Romagnoli R . Synthesis and biological activity of N-arylpiperazine-modified analogues of KN-62, a potent antagonist of the purinergic P2X7 receptor. J Med Chem. 2003; 46(8):1318-29. DOI: 10.1021/jm021049d. View

Tang L, Shukla P, Wang Z . Attenuation of opioid tolerance by antisense oligodeoxynucleotides targeting neurogranin. Eur J Pharmacol. 2006; 542(1-3):106-7. DOI: 10.1016/j.ejphar.2006.05.024. View

Chen Y, Luo F, Yang C, Kirkmire C, Wang Z . Acute inhibition of Ca2+/calmodulin-dependent protein kinase II reverses experimental neuropathic pain in mice. J Pharmacol Exp Ther. 2009; 330(2):650-9. PMC: 2713096. DOI: 10.1124/jpet.109.152165. View

Leonard A, Merrill M, Lim I, Shea M, Schulman H, Hell J . Regulation of calcium/calmodulin-dependent protein kinase II docking to N-methyl-D-aspartate receptors by calcium/calmodulin and alpha-actinin. J Biol Chem. 2002; 277(50):48441-8. DOI: 10.1074/jbc.M205164200. View

10.

Wang Z, Gardell L, Ossipov M, Vanderah T, Brennan M, Hochgeschwender U . Pronociceptive actions of dynorphin maintain chronic neuropathic pain. J Neurosci. 2001; 21(5):1779-86. PMC: 6762963. View

11.

Quillan J, Carlson K, Song C, Wang D, Sadee W . Differential effects of mu-opioid receptor ligands on Ca(2+) signaling. J Pharmacol Exp Ther. 2002; 302(3):1002-12. DOI: 10.1124/jpet.302.3.1002. View

12.

Celerier E, Laulin J, Larcher A, Le Moal M, Simonnet G . Evidence for opiate-activated NMDA processes masking opiate analgesia in rats. Brain Res. 1999; 847(1):18-25. DOI: 10.1016/s0006-8993(99)01998-8. View

13.

Smart D, Hirst R, Hirota K, Grandy D, Lambert D . The effects of recombinant rat mu-opioid receptor activation in CHO cells on phospholipase C, [Ca2+]i and adenylyl cyclase. Br J Pharmacol. 1997; 120(6):1165-71. PMC: 1564574. DOI: 10.1038/sj.bjp.0701012. View

14.

Chu L, Angst M, Clark D . Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain. 2008; 24(6):479-96. DOI: 10.1097/AJP.0b013e31816b2f43. View

15.

Niki I, Okazaki K, Saitoh M, Niki A, Niki H, Tamagawa T . Presence and possible involvement of Ca/calmodulin-dependent protein kinases in insulin release from the rat pancreatic beta cell. Biochem Biophys Res Commun. 1993; 191(1):255-61. DOI: 10.1006/bbrc.1993.1210. View

16.

Bruggemann I, Schulz S, Wiborny D, Hollt V . Colocalization of the mu-opioid receptor and calcium/calmodulin-dependent kinase II in distinct pain-processing brain regions. Brain Res Mol Brain Res. 2001; 85(1-2):239-50. DOI: 10.1016/s0169-328x(00)00265-5. View

17.

Wolfman C, Fin C, Dias M, Bianchin M, Silva R, Schmitz P . Intrahippocampal or intraamygdala infusion of KN62, a specific inhibitor of calcium/calmodulin-dependent protein kinase II, causes retrograde amnesia in the rat. Behav Neural Biol. 1994; 61(3):203-5. DOI: 10.1016/s0163-1047(05)80001-9. View

18.

Veals S, Schindler C, Leonard D, Fu X, Aebersold R, Darnell Jr J . Subunit of an alpha-interferon-responsive transcription factor is related to interferon regulatory factor and Myb families of DNA-binding proteins. Mol Cell Biol. 1992; 12(8):3315-24. PMC: 364572. DOI: 10.1128/mcb.12.8.3315-3324.1992. View

19.

Luo F, Yang C, Chen Y, Shukla P, Tang L, Wang L . Reversal of chronic inflammatory pain by acute inhibition of Ca2+/calmodulin-dependent protein kinase II. J Pharmacol Exp Ther. 2008; 325(1):267-75. DOI: 10.1124/jpet.107.132167. View

20.

Liang D, Li X, Clark J . Increased expression of Ca2+/calmodulin-dependent protein kinase II alpha during chronic morphine exposure. Neuroscience. 2004; 123(3):769-75. DOI: 10.1016/j.neuroscience.2003.10.007. View